Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS

Published on 21 Dec 2024 on TipRanks · via Yahoo Finance

Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough...

Read the rest of the article

Start tracking your investments with Statfolio

Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrou...

TipRanks · via Yahoo Finance 21 Dec 2024

Shares of Cytokinetics (NASDAQ:CYTK), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company...

Investing.com 20 Dec 2024

Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage...

Zacks · via Yahoo Finance 18 Dec 2024

Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than avera...

Zacks · via Yahoo Finance 18 Dec 2024

Teva and Sanofi reported successful results in their phase 2 study of an IBD treatment. Both stoc...

Investing.com 18 Dec 2024

Teva stock soared 26.4% to 20.88 after briefly hitting its highest point since December 2018. San...

Investor's Business Daily 17 Dec 2024

Teva and Sanofi said they plan to launch a Phase 3 trial for duvakitug pending regulatory...

Investopedia · via Yahoo Finance 17 Dec 2024

On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b...

Benzinga · via Yahoo Finance 17 Dec 2024

Teva and its partner Sanofi say 47.8% of patients with ulcerative colitis who received a high dos...

Barrons.com 17 Dec 2024

Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its...

Zacks · via Yahoo Finance 13 Dec 2024